Cyclic AMP metabolism and adenylate cyclase concentration in patients with advanced hepatic cirrhosis.

PubWeight™: 0.98‹?› | Rank: Top 15%

🔗 View Article (PMC 2966324)

Published in Gastroenterology on December 01, 1978

Authors

A Francavilla, A F Jones, T E Starzl

Articles citing this

The glucagon test in obstructive and hepatocellular jaundice. Postgrad Med J (1982) 0.77

Articles cited by this

Immunoassay of endogenous plasma insulin in man. J Clin Invest (1960) 25.67

A protein binding assay for adenosine 3':5'-cyclic monophosphate. Proc Natl Acad Sci U S A (1970) 23.79

A highly sensitive adenylate cyclase assay. Anal Biochem (1974) 20.13

Cyclic AMP. Annu Rev Biochem (1968) 8.08

A simple, sensitive method for the assay of adenyl cyclase. J Pharmacol Exp Ther (1968) 8.05

Cyclic nucleotide-dependent protein kinases. 3. Purification and properties of adenosine 3',5'-monophosphate-dependent protein kinase from bovine brain. J Biol Chem (1969) 5.37

The assay of adenosine 3',5'-cyclic monophosphate and guanosine 3',5'-cyclic monophosphate in biological materials by enzymatic radioisotopic displacement. Biochemistry (1968) 4.60

Krebs EG: Purification and characterization of a protein inhibitor of adenosine 3',5'-monophosphate-dependent protein kinases. J Biol Chem (1971) 4.41

The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84

Control of gluconeogenesis in liver. II. Effects of glucagon, catecholamines, and adenosine 3',5'-monophosphate on gluconeogenesis in the perfused rat liver. J Biol Chem (1968) 2.40

Effect of protein ingestion on splanchnic and leg metabolism in normal man and in patients with diabetes mellitus. J Clin Invest (1976) 2.27

Kinetic parameters and renal clearances of plasma adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in man. J Clin Invest (1970) 2.18

Stimulation of insulin secretion by theophylline. Nature (1967) 1.89

Effects of parathyroid hormone on plasma and urinary adenosine 3',5'-monophosphate in man. J Clin Invest (1970) 1.86

Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses. Diabetes (1971) 1.85

Separation of cyclic 3',5'-nucleoside monophosphates from other nucleotides on aluminum oxide columns. Application to the assay of adenyl cyclase and guanyl cyclase. Anal Biochem (1971) 1.83

Liver regeneration in dogs: morphologic and chemical changes. J Surg Res (1978) 1.78

USE OF LIVER ADENYL CYCLASE FOR ASSAY OF GLUCAGON IN HUMAN GASTRO-INTESTINAL TRACT AND PANCREAS. Endocrinology (1964) 1.66

Effects of catecholamines and adrenergic-blocking agents on plasma and urinary cyclic nucleotides in man. J Clin Invest (1972) 1.52

The role of cyclic AMP in the control of carbohydrate metabolism. Diabetes (1969) 1.50

Insulin secretion. Interrelationships of glucose, cyclic adenosine 3:5-monophosphate, and calcium. J Biol Chem (1975) 1.50

Effects of glucagon on adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in human plasma and urine. J Clin Invest (1970) 1.49

The role of cyclic AMP in the interaction of glucagon and insulin in the control of liver metabolism. Ann N Y Acad Sci (1971) 1.36

Antagonism between the effects of insulin and glucagon on the isolated liver. Diabetes (1969) 1.34

Hyperglucagonemia in Laennec's cirrhosis. The role of portal-systemic shunting. N Engl J Med (1974) 1.29

Organ culture of fetal rat pancreas. II. Insulin release induced by amino and organic acids, by hormonal peptides, by cationic alterations of the medium and by other agents. Biochim Biophys Acta (1969) 1.26

Glucagon-induced hyperglycemia as in index of liver function. J Clin Invest (1955) 1.26

Elevated plasma glucagon levels in cirrhosis of the liver. N Engl J Med (1973) 1.22

Effect of glucagon on net splanchnic cyclic AMP production in normal and diabetic men. J Clin Invest (1974) 1.17

Factors influencing the urinary excretion of 3',5'-adenosine monophosphate in humans. J Clin Endocrinol Metab (1970) 1.15

Plasma clearance rates and renal clearance of 3H-labeled cyclic AMP and 3H-labeled cyclic GMP in the dog. J Clin Invest (1974) 1.07

Effect of interaction between insulin and glucagon on glucose turnover and FFA concentration in normal and depancreatized dogs. Metabolism (1974) 1.06

Influence of physiologic hyperglucagonemia on basal and insulin-inhibited splanchnic glucose output in normal man. J Clin Invest (1976) 1.03

Extracellular cyclic nucleotides. Ann N Y Acad Sci (1971) 1.01

The sources of plasma cyclic AMP: studies in the rat using isoprenaline, nicotinic acid and glucagon. Eur J Clin Invest (1975) 1.00

Cirrhosis and diabetes. II. Association of impaired glucose tolerance with portal-systemic shunting in Laennec's cirrhosis. Am J Dig Dis (1971) 0.98

Enhancement by caffeine of glucagon-induced and tolbutamide-induced insulin release from isolated foetal pancreatic tissue. Lancet (1967) 0.97

Binding and biologic activity of glucagon in liver cell membranes of chronically hyperglucagonemic rats. J Biol Chem (1977) 0.93

Studies of human insulin from nondiabetic and diabetic pancreas. Diabetes (1967) 0.91

Cirrhosis and diabetes. V. Serum human growth hormone levels in Laennec's cirrhosis. J Lab Clin Med (1970) 0.88

Infection-induced hyperglucagonemia and altered hepatic response to glucagon in the rat. Am J Physiol (1974) 0.87

Effect of glucagon, adenosine-3',5'-monophosphate and theophylline on free fatty acid release by rat liver slices and on tissue levels of coenzyme A esters. Endocrinology (1969) 0.87

The secretion of insulin from foetal and postnatal rabbit pancreas in vitro in response to various substances. J Endocrinol (1969) 0.86

Plasma cyclic adenosine-3', 5'-monophosphate response to glucagon in patients with liver disease. Br Med J (1976) 0.85

Insulin release induced by glucagon in organ cultures of fetal rat pancreas. Metabolism (1966) 0.84

Hormone effects upon cyclic nucleotide excretion in man. Proc Soc Exp Biol Med (1972) 0.81

Stimulation of insulin and growth hormone secretion by adenine nucleotides in primates. J Lab Clin Med (1970) 0.79

Stimulation of insulin secretion by medium-chain triglycerides in patients with cirrhosis. Gut (1971) 0.79

Impaired responsiveness to the effect of glucagon on plasma adenosine 3':5'-cyclic monophosphate in normal man. Eur J Clin Invest (1977) 0.79

The pattern of serum triglyceride fatty acids in Laennec's cirrhosis. Am J Dig Dis (1969) 0.79

On the role of cyclic AMP in insulin release: I. Overall effects in cultured fetal rat pancreas. Ann N Y Acad Sci (1971) 0.78

Studies on the role of adenylcyclase in insulin secretion. Arch Intern Med (1969) 0.78

The effect of glucagon on plasma cyclic AMP and glucose concentrations in patients with alcoholic cirrhosis. Acta Med Scand (1977) 0.78

Study on plasma cyclic nucleotide concentrations in fasting rats. Proc Soc Exp Biol Med (1973) 0.77

Cirrhosis and diabetes. IV. Effect of potassium chloride administration on glucose and insulin metabolism. Am J Med Sci (1970) 0.76

The double glucagon test, a new liver function test. Postgrad Med J (1971) 0.76

The cyclic AMP response to glucagon. Comparison of tissue and plasma cyclic AMP levels in the rabbit. Diabetes (1977) 0.76

Articles by these authors

Evolution of liver transplantation. Hepatology (1982) 19.54

A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33

Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11

The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40

The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24

Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19

Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04

Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95

Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64

Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet (1979) 6.23

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74

Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70

Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53

Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44

Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24

Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16

Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16

Statins and hypercholesterolaemia: UK Standing Medical Advisory Committee guidelines. Lancet (1997) 4.14

Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12

Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12

Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08

Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08

Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05

Extended preservation of human liver grafts with UW solution. JAMA (1989) 3.99

Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99

Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91

The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84

Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Hepatic trisegmentectomy and other liver resections. Surg Gynecol Obstet (1975) 3.66

Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64

Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63

Hepatic Retransplantation. Transplant Proc (1985) 3.62

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54

Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49

Long-term survival after renal transplantation in humans: (with special reference to histocompatibility matching, thymectomy, homograft glomerulonephritis, heterologous ALG , AND RECIPIENT MALIGNANCY). Ann Surg (1970) 3.48

Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38

The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Delayed biliary duct obstruction after orthotopic liver transplantation. Surgery (1972) 3.26

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24

Changes in blood coagulation. Arch Surg (1966) 3.22

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Renal transplantation in baboons under FK 506. Surgery (1989) 3.17

Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg (1985) 3.17

Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16

Liver transplantation before 1 year of age. J Pediatr (1987) 3.15

In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15

The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14

Fungal infections in liver transplant recipients. Transplantation (1985) 3.07

De novo malignant tumors in organ transplant recipients. Transplant Proc (1971) 3.03

Experience with 150 liver resections. Ann Surg (1983) 3.01

A multifactorial system for equitable selection of cadaver kidney recipients. JAMA (1987) 3.01

Chronic survival after human renal homotransplantation. Lymphocyte-antigen matching, pathology and influence of thymectomy. Ann Surg (1965) 3.00

Death after transplantation; an analysis of sixty cases. Am J Med (1967) 2.99

Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98

Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95

Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95

Iatrogenic alterations of immunologic surveillance in man and their influence on malignancy. Transplant Rev (1971) 2.94

Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients. Surg Gynecol Obstet (1981) 2.92

Heart-liver transplantation in a patient with familial hypercholesterolaemia. Lancet (1984) 2.91

Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91

A better bridge for loop stomas. Br J Surg (1996) 2.90

Liver transplantation in adults. Hepatology (1982) 2.89

Veno-venous bypass without systemic anticoagulation for transplantation of the human liver. Surg Gynecol Obstet (1985) 2.88

Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87

Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84

Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81

Successful liver transplantation from crossmatch-positive donors. Transplant Proc (1981) 2.80

Studies of homograft sex and of gamma globulin phenotypes after orthotopic homotransplantation of the human liver. Surg Forum (1969) 2.80

The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79

Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. J Infect Dis (1988) 2.76

Clinical reactions and serologic changes after the administration of heterologous antilymphocyte globulin to human recipients of renal homografts. Ann Intern Med (1968) 2.72

Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66

Mechanism and modification of rejection of heterografts between divergent species. Transplant Proc (1970) 2.63

A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62

Growth-stimulating factor in regenerating canine liver. Lancet (1979) 2.61

Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60

Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59

Portal vein grafts in hepatic transplantation. Surg Gynecol Obstet (1985) 2.59

Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59

Studies of blood flow and ultrastructural changes in rejecting and nonrejecting canine orthotopic liver homografts. Surgery (1968) 2.58